ARCH Capital
ARCH资本
ARCH CapitalFund
ARCH资本
No graph yet
Mentioned in 3 articles
Coverage
AIRNA Closes $90 Million Series A to Advance Novel RNA-Editing Therapeutics
Accelerate the advancement of best-in-class drug candidates into clinical trials.
高榕创投·A Green Paper for VC Practitioners in an Era of Upheaval | 5Y View
Finding, discovering, and backing true innovators is what 5Y Capital has focused on for years, and it's also the standard we hold ourselves to as we continue to evolve.
五源资本·Vitaeon Therapeutics Completes $200 Million Series B Round to Develop Transformative Therapies for Aging-Related Degenerative Diseases
Transforming the treatment paradigm for age-related degenerative diseases, improving quality of life for millions of patients and families worldwide.
高榕创投·
